Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease.

Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jan 02;: Authors: Arihiro S, Nakashima A, Matsuoka M, Suto S, Uchiyama K, Kato T, Mitobe J, Komoike N, Itagaki M, Miyakawa Y, Koido S, Hokari A, Saruta M, Tajiri H, Matsuura T, Urashima M Abstract Background: We evaluated whether oral vitamin D supplementation during the winter and early spring reduces the incidence of influenza and upper respiratory infections in patients with inflammatory bowel disease (IBD).…

Read More

Serologic Status of Routine Childhood Vaccines, Cytomegalovirus, and Epstein-Barr Virus in Children With Inflammatory Bowel Disease.

Related Articles Serologic Status of Routine Childhood Vaccines, Cytomegalovirus, and Epstein-Barr Virus in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Dec 14;: Authors: deBruyn JCC, Soon IS, Fonseca K, Feng S, Purtzki M, Goedhart C, Kuhn S, Vanderkooi OG, Wrobel I Abstract Background: Data on the serologic status of childhood vaccines, cytomegalovirus (CMV) and Epstein-Barr virus (EBV), are limited in inflammatory bowel disease (IBD). Therefore, we evaluated vaccine coverage and seroprotection, along with CMV and EBV seropositivity, in pediatric IBD. Methods: In a cross-sectional study, demographic data, IBD…

Read More

Obesity Is Associated with Increased Risk of Colectomy in Inflammatory Bowel Disease Patients Hospitalized with Clostridium difficile Infection.

Related Articles Obesity Is Associated with Increased Risk of Colectomy in Inflammatory Bowel Disease Patients Hospitalized with Clostridium difficile Infection. Dig Dis Sci. 2018 Dec 19;: Authors: Shrestha MP, Taleban S Abstract BACKGROUND: Obesity and inflammatory bowel disease (IBD) are associated with increased risk of Clostridium difficile infection (CDI). The effect of obesity on IBD course and development of complications is poorly understood. We performed this study to examine the effect of obesity on CDI-related morbidity and mortality in hospitalized patients with IBD. METHODS: We used data from the National…

Read More

Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.

Related Articles Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2019 Jan;49(1):84-90 Authors: Sitte J, Frentiu E, Baumann C, Rousseau H, May T, Bronowicki JP, Peyrin-Biroulet L, Lopez A Abstract BACKGROUND: Although influenza and pneumococcal vaccinations for high-risk populations are recommended by current guidelines, vaccination coverage is low in patients with gastrointestinal cancer (GC) or inflammatory bowel disease (IBD). AIM: To evaluate the impact of a specialised infectious disease consultation on vaccination…

Read More

Reply to Letter on: “Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis”.

Reply to Letter on: “Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis”. J Crohns Colitis. 2018 Oct 29;: Authors: Balram B, Battat R, Al-Khoury A, D’Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T PMID: 30371761 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30371761?dopt=Abstract

Read More

Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis.

Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis. J Crohns Colitis. 2018 Oct 20;: Authors: Clos-Parals A, Rodríguez-Martínez P, Cañete F, Mañosa M, Ruiz-Cerulla A, Paúles MJ, Llaó J, Gordillo J, Fumagalli C, Garcia-Planella E, Ojanguren I, Cabré E, Guardiola J, Domènech E Abstract Background: Colonic cytomegalovirus (CMV) reactivation has been involved in steroid refractoriness in patients with active ulcerative colitis (UC). The benefits of antiviral therapy in this clinical setting are still under debate, but the burden of…

Read More

Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients with Inflammatory Bowel Diseases.

Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 Oct 13;: Authors: Khan N, Trivedi C, Kavani H, Medvedeva E, Lewis J, Yang YX Abstract BACKGROUND & AIMS: The risk of herpes zoster virus infection is increased among patients with inflammatory bowel diseases (IBD). The herpes zoster vaccine (HZV) is therefore recommended for these patients, but little is known about its effectiveness, resulting in low use. METHODS: We conducted a retrospective cohort study using data from the national veterans Affairs Healthcare System…

Read More

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H, Feathers A, Rosen MH, Malter LB, Swaminath A, IBD-ReMEdY Study (Research, Mentoring, Education New York) Abstract Background: Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD), often leading to diagnostic confusion and delays in IBD therapy escalation. This study sought…

Read More

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflamm Bowel Dis. 2018 Oct 12;24(11):2431-2441 Authors: Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC Abstract Background: Vedolizumab (ENTYVIO) is a humanized α4β7 integrin antagonist approved for the treatment of inflammatory bowel disease, which selectively blocks gut-specific lymphocyte trafficking. We evaluated the risk of opportunistic infections of interest in patients treated with vedolizumab. Methods: We determined the frequency of opportunistic infections and tuberculosis in patients receiving vedolizumab in phase…

Read More
<< Go Back